Resources Management Corp CT ADV Sells 2,582 Shares of Natera, Inc. $NTRA

Resources Management Corp CT ADV decreased its stake in Natera, Inc. (NASDAQ:NTRA) by 27.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 6,758 shares of the medical research company’s stock after selling 2,582 shares during the period. Resources Management Corp CT ADV’s holdings in Natera were worth $1,548,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in NTRA. Integrated Wealth Concepts LLC increased its holdings in shares of Natera by 6.6% in the 1st quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company’s stock worth $221,000 after buying an additional 96 shares during the last quarter. NewEdge Advisors LLC grew its holdings in shares of Natera by 68.3% during the 1st quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company’s stock valued at $644,000 after purchasing an additional 1,847 shares during the last quarter. Focus Partners Wealth grew its holdings in shares of Natera by 8.6% during the 1st quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company’s stock valued at $847,000 after purchasing an additional 474 shares during the last quarter. Sivia Capital Partners LLC bought a new position in shares of Natera during the 2nd quarter valued at $298,000. Finally, WINTON GROUP Ltd bought a new position in shares of Natera during the 2nd quarter valued at $558,000. Institutional investors own 99.90% of the company’s stock.

Insider Transactions at Natera

In other news, insider Solomon Moshkevich sold 3,000 shares of the firm’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $218.43, for a total value of $655,290.00. Following the completion of the sale, the insider directly owned 137,643 shares of the company’s stock, valued at approximately $30,065,360.49. This trade represents a 2.13% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Roelof Botha sold 78,000 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $220.31, for a total transaction of $17,184,180.00. Following the completion of the sale, the director directly owned 1,076,198 shares of the company’s stock, valued at approximately $237,097,181.38. This represents a 6.76% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 159,378 shares of company stock worth $34,640,860. 5.05% of the stock is owned by corporate insiders.

Natera Price Performance

Shares of Natera stock opened at $212.07 on Monday. The firm has a market cap of $30.37 billion, a PE ratio of -130.10 and a beta of 1.56. Natera, Inc. has a 12-month low of $131.81 and a 12-month high of $256.36. The company’s fifty day simple moving average is $206.49 and its two-hundred day simple moving average is $215.83.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Evercore reaffirmed an “outperform” rating and set a $270.00 target price on shares of Natera in a report on Friday, May 8th. BTIG Research reduced their target price on shares of Natera from $260.00 to $250.00 and set a “buy” rating on the stock in a report on Monday, May 11th. William Blair assumed coverage on shares of Natera in a report on Tuesday, April 14th. They set an “outperform” rating on the stock. Royal Bank Of Canada started coverage on shares of Natera in a report on Thursday. They set an “outperform” rating and a $275.00 target price on the stock. Finally, The Goldman Sachs Group started coverage on shares of Natera in a report on Friday, June 5th. They issued a “neutral” rating and a $245.00 price target on the stock. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $256.53.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.